Pesquisar um ensaio clínico
Outras opções de pesquisa
15 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
ALEMANHA
Baden-Württemberg
HEIDELBERG
CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease (Phase 3) - DE
Universitätsklinikum Heidelberg
ALEMANHA
Baden-Württemberg
HEIDELBERG
A Phase 2, Multicenter, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin IV - Gastroenterologie, Infektionskrankheiten, Vergiftungen
ALEMANHA
Baden-Württemberg
HEIDELBERG
Multicentre, Retrospective and Prospective Study to Assess Long Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn from Therapy With d-Penicillamine (Phase IV) - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin IV - Gastroenterologie, Infektionskrankheiten, Vergiftungen
ALEMANHA
Bayern
MÜNCHEN
CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease (Phase 3) - DE
LMU Klinikum der Universität München - Campus Großhadern
LMU Klinikum
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN1840 Administered For 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older With an Extension Period of Up To 60 Months - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 2, Single-arm, Pathologist-blinded Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in Patients With Wilson Disease Who Are Treated With ALXN1840 for 48 Weeks Followed by an Extension Treatment Period With ALXN1840 for up to an Additional 48 Weeks - AT
Institution: Information not provided - AT
ESPANHA
Andalucía
MÁLAGA
A Phase 2, Single-arm, Pathologist-blinded Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in Patients With Wilson Disease Who Are Treated With ALXN1840 for 48 Weeks Followed by an Extension Treatment Period With ALXN1840 for up to an Additional 48 Weeks - ES
Hospital Universitario Virgen de la Victoria
Unidad de Aparato Digestivo
ESPANHA
Cataluña
BARCELONA
A Phase 2, Single-arm, Pathologist-blinded Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in Patients With Wilson Disease Who Are Treated With ALXN1840 for 48 Weeks Followed by an Extension Treatment Period With ALXN1840 for up to an Additional 48 Weeks - ES
Hospital Clínic de Barcelona
Servicio de Hepatología
ESPANHA
Cataluña
SABADELL
A Phase 2, Single-arm, Pathologist-blinded Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in Patients With Wilson Disease Who Are Treated With ALXN1840 for 48 Weeks Followed by an Extension Treatment Period With ALXN1840 for up to an Additional 48 Weeks - ES
Corporación Sanitaria Parc Taulí. Hospital de Sabadell
Servicio del Aparato Digestivo
ESPANHA
Comunidad Valenciana
VALENCIA
A Phase 2, Single-arm, Pathologist-blinded Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in Patients With Wilson Disease Who Are Treated With ALXN1840 for 48 Weeks Followed by an Extension Treatment Period With ALXN1840 for up to an Additional 48 Weeks - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hepatología
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN1840 Administered For 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older With an Extension Period of Up To 60 Months - ES
Institution: Information not provided - ES
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
CHELATE STUDY: Trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson's disease -GB
Institution: Information not provided - US
Ensaio (s) clínico (s) multinacional (ais)
ESTADOS UNIDOS
Connecticut
CHESHIRE
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN1840 Administered For 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older With an Extension Period of Up To 60 Months
Alexion Pharmaceuticals, Inc.
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US